小檗碱在制备治疗三阴性乳腺癌药物中的应用
By regulating the PI3K/AKT and SRC/STAT3 signaling pathways with berberine, various drug formulations were prepared, which solved the problem of the lack of effective treatment for triple-negative breast cancer. These formulations achieved inhibition and apoptosis induction of triple-negative breast cancer cells, reduced tumor stemness, and regulated tumor biological characteristics.
Patent Information
- Application Number
- CN202610568060.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-27
- Publication Date
- 2026-07-17
AI Technical Summary
There is a lack of effective endocrine or HER2-targeted therapies for triple-negative breast cancer, and existing chemotherapy has limited efficacy and significant toxic side effects, necessitating the exploration of new treatment strategies.
Berberine (BBR) is used to regulate the PI3K/AKT and SRC/STAT3 signaling pathways, inhibit the proliferation of triple-negative breast cancer cells, induce apoptosis, reduce the proportion of CD133+ stem cells, and is then used in the treatment of these cells through pharmaceutical preparations such as tablets, capsules, granules, decoctions, or pills.
Berberine can inhibit the proliferation of triple-negative breast cancer cells in a concentration-dependent manner, induce apoptosis, reduce tumor spheroid formation ability, significantly regulate tumor biological characteristics, reduce the proportion of CD133+ stem cells, increase reactive oxygen species levels, and regulate the tumor immune microenvironment.
Smart Images
Figure CN122398796A_ABST